You are here: Industry Insights > lung cancer

News List

Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb join forces to map out lung cancer immunology firstwordpharma
December 02, 2018
A ‘rule book’ to guide precision combination immunotherapies and to speed up the development of new lung cancer treatments will be created as part of a collaboration between Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb, announc
Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial nasdaq
November 28, 2018
Bristol-Myers Squibb Company BMYannounced that the phase III CheckMate-451 study on immuno-oncology drug Opdivo in combination with Yervoy was unsuccessful....
Bristol-Myers Squibb's Opdivo combination fails maintenance therapy trial in small-cell lung cancer firstwordpharma
November 27, 2018
Bristol-Myers Squibb announced Monday that the PD-1 inhibitor Opdivo (nivolumab) in combination with its CTLA-4 inhibitor Yervoy (ipilimumab) failed to significantly
Thousands of lung cancer patients to get NHS access to Keytruda pharmatimes
November 23, 2018
MSD’s Keytruda should be funded on the NHS via the Cancer Drugs Fund for patients with the certain forms of lung cancer, according to draft guidance from the National Institute for Health and Care Excellence.
Mirati joins CR UK’s Stratified Medicine Programme pharmatimes
November 22, 2018
Mirati Therapeutics has joined Cancer Research UK’s Stratified Medicine Programme, bringing new investigational treatment options to eligible patients with advanced lung cancer.
AstraZeneca’s Imfinzi alone and in combination fails in Stage IV lung cancer trial pharmaceutical-technology
November 19, 2018
AstraZeneca has announced its Phase III MYSTIC trial of Imfinzi alone and Imfinzi combined with tremelimumab in untreated non-small cell lung cancer (NSCLC) patients failed to meet its primary endpoint.
Yuhan licences lung cancer asset to Janssen in $1.25bn deal pharmaceutical-technology
November 06, 2018
South Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.
Roche's Alecensa topples Pfizer's Xalkori in Asian patients with ALK+ advanced lung cancer pharmafile
October 25, 2018
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small cell lung cancer...
Pfizer's once-failed Vizimpro rebounds with targeted lung cancer approval fiercepharma
September 29, 2018
After flunking two late-stage trials in 2014, Pfizer's Vizimpro won an FDA green light Thursday.
Latest lung cancer data could open new avenue for Roche’s Tecentriq pharmaphorum
September 27, 2018
Roche is eyeing a new use for its checkpoint inhibitor immunotherapy Tecentriq after it posted results showing it extended patients’ lives...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page